+ Watch SENO
on My Watchlist
The Company develops, manufactures and sells minimally-invasive medical devices for the diagnosis of breast cancer.
SenoRx recently moved up significantly on news that it was cleared on a patent infringement suit. I do think this company has significant potential in the long-run as is evidenced by their 15% historical growth rate, their solid cash position and their hurdling of this patent lawsuit.I do however feel that the company has considerably overstepped its bounds in terms of current valuation. I simply can't stand behind a company that will not consistently turn a profit until late 2010/early 2011 that is already trading at nearly 5 times book. Even looking out to 2012 I would say they can hope for at best 18-21 cents per share in earnings for a 2012 forward p/e of about 37-42 based on its current price. A 2010 PEG from these guys at 2 to 2.5 would be hard to swallow but when the expectation of 2-2.5 is from 2012 its even harder. I'm going to be looking at a healthy pullback here. The news is solid, but a realistic valuation here would be between 5.50-6.25 and I think that may even be pushing it. UltraLong
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions